Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathwayAnnalisa Lonetti(University of Bologna), Francesca Chiarini(University of Modena and Reggio Emilia)Journal of Hematology & OncologyOctober 24, 201610.1186/s13045-016-0344-4Cited by 62SaveCiteExport RISWatch citationsRelated PapersPI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors|Oncotarget|2015|38